Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
PT-141 microdosing: what the evidence shows
PT-141 is FDA-approved at 1.75 mg, where nausea runs at 40% in trials. Here is what the evidence says about lower doses.
Retatrutide + GHK-Cu + ipamorelin stack
What the research says about each compound and the key data gaps before combining retatrutide, GHK-Cu, and ipamorelin with CJC-1295 No DAC.
Semax + Selank subq: together or apart?
A common question in peptide communities: should Semax and Selank be injected at the same time or spaced out? Here is what the pharmacology says.
Semax and Selank together: the evidence
Semax and Selank are Russian nootropic peptides with small, mostly Russian-language trial records. No published study has given both to the same person.
Stacking peptides on top of retatrutide
Readers ask about adding GHK-Cu, ipamorelin and CJC-1295 to retatrutide. No published human trial has tested any of those combinations.
What an IGF-1 result actually tells you
IGF-1 is a monitoring marker, not a dial to turn. What the number shows, what tesamorelin is licensed for, and why dose calls belong with a prescriber.
Can BPC-157 cause new visible veins?
BPC-157's angiogenesis data comes from cells, chick membranes and rats. No human study shows it grows new visible veins.
GLP-1 and GIP: a short incretin history
Incretins went from a failed 1906 diabetes experiment to GLP-1 and GIP drugs. Here are the dates, the discoveries, and where the evidence thins out.
GLP-1 safety in neuroendocrine tumours
A 2026 European Journal of Endocrinology review weighs the evidence on GLP-1 receptor agonists like semaglutide in neuroendocrine neoplasms.
Grey Market Semaglutide: Injection Errors
A 20-person study found untrained adults completed only 15 of 34 steps correctly when preparing grey market semaglutide from internet instructions.
MASLD and cardiovascular risk explained
MASLD affects 38% of adults worldwide and heart disease kills more of them than liver failure. Where semaglutide fits, and what remains unproven.
Semaglutide and the septic rat heart
A 2026 rat study reports semaglutide limited sepsis-related heart injury by suppressing ferroptosis. There is no human data behind it.